{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T22:19:02Z","timestamp":1785449942443,"version":"3.56.0"},"reference-count":23,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2025,12,2]],"date-time":"2025-12-02T00:00:00Z","timestamp":1764633600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2025,12,2]],"date-time":"2025-12-02T00:00:00Z","timestamp":1764633600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["headachejournal.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Headache"],"published-print":{"date-parts":[[2026,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To describe the real\u2010world safety, tolerability, and effectiveness of eptinezumab for chronic migraine prevention in Australia.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Eptinezumab is a relatively new medication for treatment\u2010resistant chronic migraine prevention. It was only introduced onto the Australian Pharmaceutical Benefits Scheme in August 2023, so there are limited real\u2010world Australian data regarding its tolerability and effectiveness.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This is a single center retrospective audit of patients receiving eptinezumab for chronic migraine prevention between 1 September 2023 and 31 December 2024. Headache characteristics were compared at baseline and 3 months after eptinezumab administration. Primary outcomes were mean reductions in monthly headache days (MHD) and monthly migraine days (MMD). Secondary outcomes were mean monthly reductions in acute abortive medications, and adverse events.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Of the 60 patients who received eptinezumab during the study period, a total of 54 patients with complete medical records and headache diaries were used in the statistical analysis. The majority were female (43\/54, 80%) with mean age 41.7\u2009years (SD 11.4). Three months after eptinezumab infusion, MMD reduced from 23.0 to 15.4\u2009days (\n                      <jats:italic>p<\/jats:italic>\n                      value &lt;0.001), and MHD reduced from 26.5 to 19.2\u2009days (\n                      <jats:italic>p<\/jats:italic>\n                      value &lt;0.001). Acute analgesic use decreased from 16.2 to 11.1\u2009days (\n                      <jats:italic>p<\/jats:italic>\n                      value&lt;0.001). The vast majority (94%, 51\/54) had no immediate adverse events. Of 22 patients with 6\u2010month post infusion data, mean MMD and MHD decreased to 11.0 (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001) and 17.8\u2009days (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001), respectively, from baseline. Statistically significant reductions to both co\u2010primary outcomes were achieved in those with pre\u2010existing medication\u2010overuse headache and those who had previously not responded to onabotulinumtoxinA, fremanezumab, and galcanezumab.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Our findings show that eptinezumab is a safe, well\u2010tolerated migraine prophylactic that decreases monthly migraine and headache days in a small sample of Australian patients with treatment\u2010resistant chronic migraine. Further prospective studies with larger sample sizes and longer follow\u2010up data are needed to confirm findings of this study.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/head.70015","type":"journal-article","created":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T05:45:06Z","timestamp":1764740706000},"page":"108-117","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["A retrospective audit of the real\u2010world safety and effectiveness profile of eptinezumab for treatment\u2010resistant chronic migraine in Australia"],"prefix":"10.1111","volume":"66","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2292-8155","authenticated-orcid":false,"given":"Lakshini","family":"Gunasekera","sequence":"first","affiliation":[{"name":"Alfred Hospital  Melbourne Victoria Australia"},{"name":"Monash University  Melbourne Victoria Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuli","family":"Cheng","sequence":"additional","affiliation":[{"name":"Alfred Hospital  Melbourne Victoria Australia"},{"name":"Monash University  Melbourne Victoria Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma","family":"Foster","sequence":"additional","affiliation":[{"name":"Alfred Hospital  Melbourne Victoria Australia"},{"name":"Monash University  Melbourne Victoria Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shobi","family":"Sivathamboo","sequence":"additional","affiliation":[{"name":"Alfred Hospital  Melbourne Victoria Australia"},{"name":"Monash University  Melbourne Victoria Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terence","family":"O'Brien","sequence":"additional","affiliation":[{"name":"Alfred Hospital  Melbourne Victoria Australia"},{"name":"Monash University  Melbourne Victoria Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helmut","family":"Butzkueven","sequence":"additional","affiliation":[{"name":"Alfred Hospital  Melbourne Victoria Australia"},{"name":"Monash University  Melbourne Victoria Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jayashri","family":"Kulkarni","sequence":"additional","affiliation":[{"name":"Alfred Hospital  Melbourne Victoria Australia"},{"name":"Monash University  Melbourne Victoria Australia"},{"name":"HER Centre  Melbourne Victoria Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8543-7767","authenticated-orcid":false,"given":"Elspeth","family":"Hutton","sequence":"additional","affiliation":[{"name":"Alfred Hospital  Melbourne Victoria Australia"},{"name":"Monash University  Melbourne Victoria Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,12,2]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2022.930383"},{"key":"e_1_2_9_3_1","volume-title":"Eptinezumab","author":"Pharmaceutical Benefits Scheme","year":"2025"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.18773\/austprescr.2025.017"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.13968"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-024-01764-9"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1177\/03331024231170807"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12883-023-03204-8"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12883-022-02774-3"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2022.01.006"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-022-01386-z"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-021-01227-5"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1177\/0333102419858355"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12883-022-02914-9"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.14120"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/1440-1681.13700"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.14767"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/ene.15670"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.14206"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.14036"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-022-01482-0"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000009169"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1177\/03331024241288875"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-024-01788-1"}],"container-title":["Headache: The Journal of Head and Face Pain"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/headachejournal.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/head.70015","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/headachejournal.onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/head.70015","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/headachejournal.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/head.70015","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,14]],"date-time":"2026-03-14T05:32:40Z","timestamp":1773466360000},"score":1,"resource":{"primary":{"URL":"https:\/\/headachejournal.onlinelibrary.wiley.com\/doi\/10.1111\/head.70015"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,2]]},"references-count":23,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["10.1111\/head.70015"],"URL":"https:\/\/doi.org\/10.1111\/head.70015","archive":["Portico"],"relation":{},"ISSN":["0017-8748","1526-4610"],"issn-type":[{"value":"0017-8748","type":"print"},{"value":"1526-4610","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,2]]},"assertion":[{"value":"2025-06-15","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-10-07","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-12-02","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}